Covid 19 Research using Clinical Trials (Home Page)
Report for D005764: Gastroesophageal Reflux NIH
(Synonyms: Gastroesophageal Refl, Gastroesophageal Reflux)
Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation
Correlated Drug Terms (8)
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug1162 | IW-3718 Wiki | 0.82 |
| drug1395 | Lung Function tests Wiki | 0.58 |
| drug1640 | None - NA Wiki | 0.58 |
| drug885 | Exercise physiology Wiki | 0.58 |
| drug2084 | Respiratory symptoms, symptoms of anxiety and depression, and post-traumatic stress screening Wiki | 0.58 |
| drug884 | Exercise capacity Wiki | 0.58 |
| drug1040 | Health-related quality of life Wiki | 0.58 |
| drug2950 | placebo Wiki | 0.31 |
Correlated MeSH Terms (3)
| Name (Synonyms) | Correlation | |
|---|---|---|
| D004942 | Esophagitis, Peptic NIH | 0.82 |
| D004932 | Esophageal and Gastric Varices NIH | 0.58 |
| D003108 | Colonic Diseases NIH | 0.58 |
Correlated HPO Terms (2)
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0002020 | Gastroesophageal reflux HPO | 1.00 |
| HP:0002040 | Esophageal varix HPO | 0.58 |
There are 3 clinical trials
Clinical Trials
1 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standard-dose proton pump inhibitors (PPIs).
NCT03561090 Gastroesophageal Reflux Disease (GERD) Drug: IW-3718 Drug: placebo MeSH:Gastroesophageal Reflux Esophagitis, Peptic
HPO:Gastroesophageal reflux
Primary Outcomes
Measure: Proportion of Overall Heartburn Responders Time: Week 8
Secondary Outcomes
Measure: Proportion of Overall Heartburn Responders Among Participants With a Baseline Weekly Heartburn Severity Score (WHSS) ≥ 3 Time: Week 8
Measure: Percent Change From Baseline to Week 8 in WHSS Time: Baseline, Week 8
Measure: Percent Change From Baseline to Week 8 in Weekly Regurgitation Frequency Score (WRFS) Time: Baseline, Week 8
Measure: Proportion of Heartburn-Free (Daily Heartburn Severity Score [DHSS]=0) Days During the 8-Week Treatment Period Time: up to Week 8
Measure: Proportion of Overall Regurgitation Responders Time: Week 8
Measure: Proportion of Days When Heartburn Did Not Occur (DHSS=0) or Was Very Mild (DHSS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days When Regurgitation Did Not Occur (Daily Regurgitation Frequency Scores [DRFS]=0) or Rarely Occurred (DRFS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Regurgitation-Free (DRFS=0) Days During the 8-Week Treatment Period Time: Week 8
Measure: Change From Baseline to Week 8 in Each Modified Reflux Symptom Questionnaire Electronic Diary (mRESQ) Item Time: Baseline, Week 8
Measure: Proportion of Nights With Difficulty Falling Asleep Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days With Nighttime Awakening Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Number of Degree of Relief (of Heartburn/Regurgitation/Overall GERD Symptoms) Responders Time: up to Week 8
Measure: Change From Baseline to Week 8 in Heartburn/Regurgitation/Overall GERD Symptoms Bothersomeness Time: Baseline, Week 8
Measure: Proportion of Days With Rescue Medication Use During the 8-Week Treatment Period Time: up to Week 8
2 A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Trial of Oral IW-3718 Administered to Patients With Gastroesophageal Reflux Disease While Receiving Proton Pump Inhibitors
Primary Outcomes
Measure: Proportion of Overall Heartburn Responders Time: Week 8Secondary Outcomes
Measure: Proportion of Overall Heartburn Responders Among Participants With a Baseline Weekly Heartburn Severity Score (WHSS) ≥ 3 Time: Week 8Measure: Percent Change From Baseline to Week 8 in WHSS Time: Baseline, Week 8
Measure: Percent Change From Baseline to Week 8 in Weekly Regurgitation Frequency Score (WRFS) Time: Baseline, Week 8
Measure: Proportion of Heartburn-Free (Daily Heartburn Severity Score [DHSS]=0) Days During the 8-Week Treatment Period Time: up to Week 8
Measure: Proportion of Overall Regurgitation Responders Time: Week 8
Measure: Proportion of Days When Heartburn Did Not Occur (DHSS=0) or Was Very Mild (DHSS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days When Regurgitation Did Not Occur (Daily Regurgitation Frequency Scores [DRFS]=0) or Rarely Occurred (DRFS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Regurgitation-Free (DRFS=0) Days During the 8-Week Treatment Period Time: Week 8
Measure: Change From Baseline to Week 8 in Each Modified Reflux Symptom Questionnaire Electronic Diary (mRESQ) Item Time: Baseline, Week 8
Measure: Proportion of Nights With Difficulty Falling Asleep Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days With Nighttime Awakening Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Number of Degree of Relief (of Heartburn/Regurgitation/Overall GERD Symptoms) Responders Time: up to Week 8
Measure: Change From Baseline to Week 8 in Heartburn/Regurgitation/Overall GERD Symptoms Bothersomeness Time: Baseline, Week 8
Measure: Proportion of Days With Rescue Medication Use During the 8-Week Treatment Period Time: up to Week 8
The objective of this study is to evaluate the safety and efficacy of IW-3718 administered to patients with GERD who continue to have persistent symptoms, such as heartburn and regurgitation, while receiving once-daily (QD), standarddose proton pump inhibitors (PPIs).
NCT03561883 Gastroesophageal Reflux Disease (GERD) Drug: IW-3718 Drug: placebo MeSH:Gastroesophageal Reflux Esophagitis, Peptic
HPO:Gastroesophageal reflux
Primary Outcomes
Measure: Proportion of Overall Heartburn Responders Time: Week 8
Secondary Outcomes
Measure: Proportion of Overall Heartburn Responders Among Participants With a Baseline Weekly Heartburn Severity Score (WHSS) ≥ 3 Time: Week 8
Measure: Percent Change From Baseline to Week 8 in WHSS Time: Baseline, Week 8
Measure: Percent Change From Baseline to Week 8 in Weekly Regurgitation Frequency Score (WRFS) Time: Baseline, Week 8
Measure: Proportion of Heartburn-Free (Daily Heartburn Severity Score [DHSS]=0) Days During the 8-Week Treatment Period Time: up to Week 8
Measure: Proportion of Overall Regurgitation Responders Time: up to Week 8
Measure: Proportion of Days When Heartburn Did Not Occur (DHSS=0) or Was Very Mild (DHSS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days When Regurgitation Did Not Occur (Daily Regurgitation Frequency Scores [DRFS]=0) or Rarely Occurred (DRFS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Regurgitation-Free (DRFS=0) Days During the 8-Week Treatment Period Time: Week 8
Measure: Change From Baseline to Week 8 in Each Modified Reflux Symptom Questionnaire Electronic Diary (mRESQ) Item Time: Baseline, Week 8
Measure: Proportion of Nights With Difficulty Falling Asleep Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days With Nighttime Awakening Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Number of Degree of Relief (of Heartburn/Regurgitation/Overall GERD Symptoms) Responders Time: up to Week 8
Measure: Change From Baseline to Week 8 in Heartburn/Regurgitation/Overall GERD Symptoms Bothersomeness Time: Baseline, Week 8
Measure: Proportion of Days With Rescue Medication Use During the 8-Week Treatment Period Time: up to Week 8
3 Endoscopy-related Phone Consultation During the COVID-19 Outbreak: Impact on Attendance and Patient/Consultant Perspectives From a Tertiary Australian Hospital
Primary Outcomes
Measure: Proportion of Overall Heartburn Responders Time: Week 8Secondary Outcomes
Measure: Proportion of Overall Heartburn Responders Among Participants With a Baseline Weekly Heartburn Severity Score (WHSS) ≥ 3 Time: Week 8Measure: Percent Change From Baseline to Week 8 in WHSS Time: Baseline, Week 8
Measure: Percent Change From Baseline to Week 8 in Weekly Regurgitation Frequency Score (WRFS) Time: Baseline, Week 8
Measure: Proportion of Heartburn-Free (Daily Heartburn Severity Score [DHSS]=0) Days During the 8-Week Treatment Period Time: up to Week 8
Measure: Proportion of Overall Regurgitation Responders Time: up to Week 8
Measure: Proportion of Days When Heartburn Did Not Occur (DHSS=0) or Was Very Mild (DHSS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days When Regurgitation Did Not Occur (Daily Regurgitation Frequency Scores [DRFS]=0) or Rarely Occurred (DRFS=1) During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Regurgitation-Free (DRFS=0) Days During the 8-Week Treatment Period Time: Week 8
Measure: Change From Baseline to Week 8 in Each Modified Reflux Symptom Questionnaire Electronic Diary (mRESQ) Item Time: Baseline, Week 8
Measure: Proportion of Nights With Difficulty Falling Asleep Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Proportion of Days With Nighttime Awakening Due to GERD During the 8-Week Treatment Period Time: Week 8
Measure: Number of Degree of Relief (of Heartburn/Regurgitation/Overall GERD Symptoms) Responders Time: up to Week 8
Measure: Change From Baseline to Week 8 in Heartburn/Regurgitation/Overall GERD Symptoms Bothersomeness Time: Baseline, Week 8
Measure: Proportion of Days With Rescue Medication Use During the 8-Week Treatment Period Time: up to Week 8
The aim of this study is to evaluate patient and consultant experiences with phone consultations for endoscopy-related outpatient appointments during the COVID-19 outbreak.
NCT04344964 Colon Polyp Colon Disease Reflux, Gastroesophageal Varices, Esophageal Other: None - NA MeSH:Colonic Diseases Gastroesophageal Reflux Esophageal and Gastric Varices
HPO:Esophageal varix Gastric varix Gastroesophageal reflux
Primary Outcomes
Description: percentage of patients that did not answer phone calls (at least 3 calls) or with documented FTA for the retrospective group.
Measure: Failed to attend patients Time: 2 months
Secondary Outcomes
Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020 - MSF and PAT-VC questionnaires). These are mostly Likert-scale response mode statements.
Measure: Patient satisfaction with the phone consult Time: 2 months
Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020). These are mostly Likert-scale response mode statements.
Measure: Consultant satisfaction with the phone consult Time: 2 months
HPO Nodes
HP:0002020: Gastroesophageal reflux
Genes 347
PPM1D DNM1 SHANK3 CCDC47 CTBP1 COL13A1 DHCR7 LIMK1 VAMP1 LBR ELP1 SCN3A KCNAB2 GPHN SLC1A4 SLC13A5 AFF4 SEC63 FOXG1 FGFR3 ACTL6B POLG TCF4 COG7 ELN CNKSR2 STAG1 SMG9 SLC1A2 ATP6V1A ATRX RRM2B AMER1 NIPBL SAMD9 RAI1 SMC1A SALL1 TYMP PRDM16 CHMP1A FGFRL1 SCN8A FAM13A STN1 DSP SYNJ1 GMNN CDKL5 WWOX NFIX CCR6 TRAK1 RRM2B POLG2 PRKCSH RREB1 ALDH18A1 MCEE SLC5A7 ARFGEF2 PHGDH SEMA3E NUP62 ADNP NTRK2 LONP1 WDR26 CHD7 PHOX2B ORC6 SMC3 SHANK3 GABRA2 RET NALCN KMT2A RAI1 HLA-DRB1 SLC35A2 KAT6A TFAP2A CAMK2B RHBDF2 FARSB HDAC8 NIPBL FLNA COL13A1 RERE MYMK ASXL1 NRXN1 ADAR MECP2 MAP3K7 TMTC3 TOP3A MLXIPL CDKL5 CACNA1B ASCC1 HLA-DQA1 IRF5 MECP2 SFTPC ABCA3 SLC19A2 KIAA0319L SKI RAD21 CNTNAP1 PIGN PIGN GABBR2 NALCN ARVCF PAK1 FLCN ATRX KIAA0586 RERE FCSK SFTPA1 KLHL7 LAMA2 SSR4 POLG IQSEC2 SKI SLC2A10 GEMIN4 HNRNPH2 ALDH18A1 POLG2 BAZ1B RTEL1 TAF1 CYFIP2 GALC ASCL1 EXT2 SFTPA2 NTNG1 TSPYL1 ASXL1 LRP5 OCRL ZSWIM6 ATP7A SLC46A1 NEXMIF TBX4 AP3B2 EEF1A2 GP1BB KCNB1 TCF4 ATP11A LTBP4 NEDD4L SMC1A TECPR2 NONO GTF2IRD1 ADAMTS2 UFD1 SHROOM4 LETM1 MUC5B STAG1 STXBP1 DDC TRIP4 RAD21 NUS1 HLA-DQB1 CACNA1A RPL10 MYO9A PORCN SH2B1 MECP2 TWNK RFC2 ATN1 SLC6A5 IRF5 AGRN GABRG2 CTHRC1 CRLF1 GRIN2D ADAT3 SNAP25 SYT1 SLC9A6 NONO CAV1 GTF2I TWIST1 MID1 ATAD1 EXT2 SMC3 ARNT2 NUP214 HRAS CLTC PIGT NSD2 STXBP1 DEAF1 DHCR7 PIEZO2 TERC BRAF CLIP2 PSPH NPHS1 POGZ COMT NECAP1 SEC23A SZT2 NRXN1 DDOST HLA-DRB1 JMJD1C EHMT1 AARS1 FMR1 WNK1 UBA5 KIF1A SOX5 ARV1 SMC1A PCGF2 RPL10 TSPYL1 HIRA SLC6A3 MRPS34 PUF60 RETREG1 SYT1 FOXG1 RNF125 YWHAG FLNA CPLX1 PGM3 NOS1 AFF4 SLC25A1 ORC4 TBX1 PARS2 TBC1D24 KAT6B EBF3 ATRX ABCD4 ORC1 PYCR1 RERE WASHC5 FLII SETD5 NEXMIF MAP3K7 CCDC22 PACS1 TRAPPC12 KCNA2 ELP1 ELN POGZ DDOST PPP3CA PARN MED12 ASPA FBXL4 GABRB2 SLC25A24 WHCR CNTNAP2 CCN2 CHAMP1 CHAT ATP6 TBL2 CTCF GLRB ARF1 SLC18A3 PIEZO1 TBX1 CAV1 GABRD GLRA1 USP7 KMT2A ERMARD PIGN SCN9A FGF12 RPL10 CSPP1 ATRX DHDDS CLCN4 SLC35A2 PSAP FBN1 SEC24C GABRA5 CAMTA1 TCF4 HIVEP2 MAGEL2 MECP2 CCR6 SKI STAC3 UBA5 RAI1 KCNA2 HCN1 SYT2 SNRPB SLC6A3 MSR1 TERT TRMT10C SLC25A4 CDC6 SON MAP1B SYNGAP1 DPP9 CCN2 HDAC8 MEIS2 ARID2 Protein Mutations 1
D961H SNP 0
Primary Outcomes
Description: percentage of patients that did not answer phone calls (at least 3 calls) or with documented FTA for the retrospective group.
Measure: Failed to attend patients Time: 2 monthsSecondary Outcomes
Description: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020 - MSF and PAT-VC questionnaires). These are mostly Likert-scale response mode statements.
Measure: Patient satisfaction with the phone consult Time: 2 monthsDescription: Assessed through an online/hardcopy questionnaire based on previous studies on telehealth (adapted from Barsom et al. 2020). These are mostly Likert-scale response mode statements.
Measure: Consultant satisfaction with the phone consult Time: 2 months